Clinical Trials on Non-Hodgkin's Disease

Total 380047 results

Keimyung University Dongsan Medical Center
Otsuka Pharmaceutical Co., Ltd.

Recruiting

Allogeneic Stem Cell Transplantation in Relapsed/Refractory T-, NK/T-cell Lymphomas (RRTCLAlloSCT)

Lymphoma, Extranodal NK-T-Cell | T-cell Non-Hodgkin Lymphoma

Korea, Republic of
Bayside Health

Completed

Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma

Non-Hodgkin's Lymphoma | Hodgkin's Disease

Australia
Azienda Ospedaliera Città della Salute e della...

Completed

Retrospective Analysis on Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Z-BEAM Plus ASCT

Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma
Versailles Hospital

Not yet recruiting

Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma (LYMPHO-CoVac)

Vaccination Failure | Non-hodgkin Lymphoma,B Cell
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

B-cell Non-Hodgkin's Lymphoma

China
Stanford University
Kite Pharma

Recruiting

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Non-Hodgkin Lymphoma | Large B-cell Lymphoma

United States
Shanghai Henlius Biotech

Completed

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

B-cell Non Hodgkin's Lymphoma
Shanghai Henlius Biotech

Completed

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

B-cell Non Hodgkin's Lymphoma

China
The Methodist Hospital Research Institute

Withdrawn

Relapsed and/or Refractory Non-Hodgkin Lymphoma Study (COMBOSTAT)

Non-Hodgkin Lymphoma
Amgen

Completed

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

B-Cell Non Hodgkin Lymphoma

United States, Spain, United Kingdom, Belgium, Italy, Australia, Canada, Puerto Rico
National Cancer Institute (NCI)

Withdrawn

Testing the Safety of CB-5339 in Patients With Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma

United States
The First Affiliated Hospital of Soochow University
Fundamenta Therapeutics, Ltd.

Recruiting

ThisCART19A for B-NHL Relapsed After Auto-CAR T

B Cell Lymphoma | CAR | Relapsed Non-Hodgkin Lymphoma

China
Institut Bergonié
National Cancer Institute, France

Completed

Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial (FRAIL-06)

Lymphoma

France
Menarini Group

Terminated

MEN1309 I.v. Infusion in Pts With CD205-positive Metastatic Solid Tumors and Relapsed or Refractory NHL Ph I Study (CD205SHUTTLE)

Metastatic Solid Tumors | Relapsed/Refractory Non-Hodgkin Lymphoma

Italy, Spain, Belgium, United Kingdom
Beth Israel Deaconess Medical Center

Completed

Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Bayer

Completed

Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell | Non-Hodgkin's Lymphoma | Lymphoma, Low-Grade

Japan
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma

Lymphoma

United States
Bristol-Myers Squibb

Active, not recruiting

A Rollover Study of CC-122

Non-Hodgkin Lymphoma

Netherlands, France, United States, Japan
Reid Merryman, MD
AbbVie; Genmab

Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Follicular Lymphoma | Low Grade Non-Hodgkin's Lymphoma, Adult

United States
The Lymphoma Academic Research Organisation

Active, not recruiting

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

France, Belgium
International Extranodal Lymphoma Study Group (IELSG)

Completed

A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae (IELSG27)

Non-Hodgkin Lymphoma

Spain, Italy, Switzerland, Chile
Université de Sherbrooke

Unknown

Early Evaluation of the Response of Large B Cell Non Hodgkin's Lymphoma to Chemotherapy by PET/CT

Lymphoma, Large-Cell

Canada
Northwestern University
National Cancer Institute (NCI)

Not yet recruiting

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

B-Cell Non-Hodgkin Lymphoma

United States
Chongqing Precision Biotech Co., Ltd
Peking University Cancer Hospital & Institute

Recruiting

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma

B Cell Lymphoma | Non Hodgkin Lymphoma

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

Non-Hodgkin's Lymphoma

United States
Nanjing Yoko Biomedical Co., Ltd.

Completed

A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

B-Cell Lymphoma

China
M.D. Anderson Cancer Center
Genentech, Inc.

Completed

Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

Lymphoma

United States
University of California, San Francisco

Terminated

A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

Lymphoma, B-Cell

United States
Abbott

Completed

Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin's Lymphoma

United States
National Cancer Institute (NCI)

Completed

Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation

Lymphoma, B-Cell | Leukemia, B-cell | Lymphoma, Hodgkins | Lymphoma, Non-hodgkins

United States
Acrotech Biopharma Inc.

Withdrawn

Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn

Non Hodgkin's Lymphoma
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Effect of Weekly PROCRIT (Epoetin Alfa) or Placebo on Anemia and Quality of Life in Children With Cancer Undergoing Chemotherapy

Leukemia | Anemia | Hodgkin Disease | Lymphoma, Non-hodgkin
Sana Biotechnology

Recruiting

Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) (VIVID)

Non Hodgkin's Lymphoma | Large B-cell Lymphoma

United States
Clinica Universidad de Navarra, Universidad de...
Spanish National Health System

Unknown

Rituximab and Autologous Effector Lymphocytes in Non-Hodgkin Follicular Lymphoma in Response to First Line Chemotherapy

Follicular Lymphoma | Follicular Non-Hodgkin´s Lymphoma | Autologous Effector Lymphocytes

Spain
Biogen

Completed

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

United States, Canada
Massachusetts General Hospital
The Leukemia and Lymphoma Society

Completed

Meloxicam vs Placebo for Mobilization

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Hematopoietic Stem Cells

United States
Fondazione Italiana Linfomi ONLUS

Completed

A Phase II Study for Patients With Indolent Non-follicular Non-Hodgkin's Lymphoma (IIL INFL09)

Non-Hodgkin's Lymphoma | Indolent Non-follicular

Italy
University Hospital, Geneva

Active, not recruiting

A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma (FRILLY)

Aggressive B-Cell Non-Hodgkin Lymphoma

Switzerland
Chinese PLA General Hospital

Recruiting

CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas (CART30)

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma

China
Western Regional Medical Center

Withdrawn

Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)

Lymphoma | Hodgkin's Lymphoma | Non-hodgkin's Lymphoma

United States
Washington University School of Medicine

Completed

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Washington University School of Medicine

Completed

Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Shams Shakil
Celgene

Completed

Azacitidine With Rituximab, Vincristine, and Cyclophosphamide in Refractory Lymphoma

Lymphoma | Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
King Faisal Specialist Hospital & Research Center

Completed

Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT

Lymphoma, Non-Hodgkin | Hodgkin Disease
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Celgene Corporation

Completed

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Refractory/Relapsed Indolent Non-Hodgkin Lymphoma

United States
Zhejiang University
Yake Biotechnology Ltd.

Not yet recruiting

CD79b CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

Relapsed and/or Refractory Acute Lymphoblastic Leukemia | Relapsed and/or Refractory B-cell Non-Hodgkin's Lymphoma

China
Andres J. M. Ferreri
Amgen

Completed

Secondary Prophylaxis in Non-Hodgkin Lymphoma (NHL) and Chemotherapy-induced Thrombocytopenia (ProRom)

Non-Hodgkin Lymphoma

Italy
Icahn School of Medicine at Mount Sinai

Unknown

Host Dendritic Cells in Allograft Patients

Multiple Myeloma | Hodgkin's Disease | Chronic Lymphocytic Lymphoma | Relapsed Non-Hodgkin's Lymphoma

United States
Marcela V. Maus, M.D.,Ph.D.
Kite, A Gilead Company

Active, not recruiting

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Non Hodgkin Lymphoma | Neurotoxicity | Neurotoxicity Syndromes | Cytokine Release Syndrome | Refractory Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma

United States
SymBio Pharmaceuticals

Completed

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan

Clinical Trials on Non-Hodgkin's Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations